Novo reported a strong quarter driven by Victoza, Levemir and currency tailwinds. Q3 revenue increased by 20% (8% in LC) to DKK26.8bn, with Victoza growing by 20% (LC), Levemir by 10% (LC) and currency contributing 12% to the LC growth. Others in the portfolio lent a steady support. The operating expenses were dominated primarily by launch costs related to Saxenda and NovoEight, preparatory expenses for Tresiba and sales force investments in some markets, offset to some extent by lower R&
